Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Windtree Therapeutics ( (WINT) ).
On July 29, 2025, Windtree Therapeutics, Inc. announced the resignation of Leanne Kelly from its Board of Directors, where she served as the chairperson of the Audit Committee. Subsequently, on August 3, 2025, Andrew Kucharchuk was appointed to the Board and as the new chairperson of the Audit Committee. Mr. Kucharchuk brings extensive financial leadership experience from his previous roles at various companies, including Cero Therapeutics Holdings, Inc. and Theralink Technologies, Inc.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 10,924,880
Technical Sentiment Signal: Sell
Current Market Cap: $17.2M
For an in-depth examination of WINT stock, go to TipRanks’ Overview page.